PaxSafe's Mark Talens on why pharma supply chain AI fails before it starts — and the data foundry framework that changes that.
|Articles|January 19, 2017
NICE Delays Drug Appraisal Fee Plan
January 19, 2017
Advertisement
The UK’s National Institute of Health and Care Excellence (NICE) announced this week that its plans to charge companies for its appraisals of drugs, medical devices and diagnostics have been put on hold until the UK’s new government completes its life sciences strategy, the
NICE's plan to charge for appraisals, proposed in October 2016, would see companies pay fees of up to £282,000 ($347,700) for each cost-effectiveness assessment.
NICE’s chief executive, Sir Andrew Dillon, said in a statement: “We have been working to create a new funding model for technology evaluation to meet the government’s challenge to drive efficiency and deliver better value. We’ve agreed with the Department of Health to wait for the Government’s life sciences strategy to be completed before we move forward with our plans.”
See more at: http://www.raps.org/Regulatory-Focus/News/2017/01/16/26612/NICE-Halts-Plans-to-Charge-for-Appraisals/#sthash.QMhLynIB.dpuf
Advertisement
Related to this article
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.
Why purpose is becoming the most important infrastructure in AI-driven health care technology.
Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
The future of engagement won’t be defined by how much information reaches health care professionals, but by how precisely it supports the decision at hand.
Advertisement
Advertisement
Trending on PharmExec
1
Prediction Markets Expose a Gap in Pharmaceutical Vendor Contracts
2
Bausch + Lomb Appoints Thomas Appio as Interim CEO
3
The Bottlenecks That Slow Manufacturer Response to Increased Demand for Production
4
The Manufacturing Issues That Continue to Contribute to Drug Shortages
5